Abstract
Pre-existing Neutralizing antibody to adenoviral vectors is one of the limiting factors to the successful application of vectors in Gene Therapy. Studies have demonstrated a high and low prevalence of nab to Ad5 and Ad35 respectively in Africa, Asia, America, and Europe. While most report focused on the negative impact of this nab, a few have demonstrated successful gene transfer in the presence of nab. To further understand the Clinical implications of these findings, we studied the neutralization of Therapeutic and lower doses of the viruses using high and low concentration of pooled Human IgG and relate it to the existing titer of nab in the pooled Human IgG, Human Sera, and Sera from monkeys previously immunized and boosted with ad5 and ad35.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
